CD38 and B-cell chronic lymphocytic leukemia: However, CLL cells treated with the CD38-blocking mAb AT-1 produced a noticeable decrease in pSyk activation after 1-h, which was coupled to decrease in the proliferative (Ki67+) output of CLL cells (Figure 5C).